Nectar Lifesciences Limited (NECLIFE.NS)
INR 21.88
(-3.48%)
INR 21.88
(-3.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.53 Billion INR | 59.17% |
| 2022 | 539.47 Million INR | -36.55% |
| 2021 | 1.58 Billion INR | 53.61% |
| 2020 | 1.1 Billion INR | -48.0% |
| 2019 | 2.2 Billion INR | -9.69% |
| 2018 | 2.64 Billion INR | -2.27% |
| 2017 | 2.36 Billion INR | 3.35% |
| 2016 | 2.24 Billion INR | -14.78% |
| 2015 | 2.39 Billion INR | -0.49% |
| 2014 | 2.66 Billion INR | -2.07% |
| 2013 | 2.9 Billion INR | -15.26% |
| 2012 | 2.95 Billion INR | 18.65% |
| 2011 | 2.49 Billion INR | 3.54% |
| 2010 | 2.4 Billion INR | 18.26% |
| 2009 | 2.14 Billion INR | 46.24% |
| 2008 | 1.39 Billion INR | -7.43% |
| 2007 | 1.5 Billion INR | 73.68% |
| 2006 | 865.43 Million INR | 10.74% |
| 2005 | 781.51 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 398.03 Million INR | -19.25% |
| 2023 Q1 | 360.13 Million INR | 0.09% |
| 2023 FY | - INR | 59.17% |
| 2023 Q4 | 485.03 Million INR | 14.96% |
| 2023 Q3 | 421.9 Million INR | 12.59% |
| 2023 Q2 | 374.73 Million INR | 4.05% |
| 2022 Q3 | 146.85 Million INR | 343.5% |
| 2022 Q1 | 421.72 Million INR | 34.33% |
| 2022 FY | - INR | -36.55% |
| 2022 Q2 | 33.11 Million INR | -92.15% |
| 2022 Q4 | 359.81 Million INR | 145.01% |
| 2021 FY | - INR | 53.61% |
| 2021 Q4 | 313.95 Million INR | -33.37% |
| 2021 Q3 | 471.19 Million INR | 44.74% |
| 2021 Q2 | 325.54 Million INR | -19.64% |
| 2021 Q1 | 405.12 Million INR | 289.87% |
| 2020 FY | - INR | -48.0% |
| 2020 Q2 | 320.01 Million INR | 86.34% |
| 2020 Q1 | 171.73 Million INR | -14.24% |
| 2020 Q4 | -213.37 Million INR | -163.86% |
| 2020 Q3 | 334.13 Million INR | 4.41% |
| 2019 Q3 | 565.68 Million INR | 15.34% |
| 2019 Q4 | 200.25 Million INR | -64.6% |
| 2019 Q2 | 490.43 Million INR | -23.51% |
| 2019 FY | - INR | -9.69% |
| 2019 Q1 | 641.2 Million INR | 299.68% |
| 2018 Q2 | 658.27 Million INR | 7.09% |
| 2018 Q1 | 614.66 Million INR | 0.0% |
| 2018 FY | - INR | -2.27% |
| 2018 Q4 | 160.43 Million INR | -75.98% |
| 2018 Q3 | 667.9 Million INR | 1.46% |
| 2017 FY | - INR | 3.35% |
| 2016 FY | - INR | -14.78% |
| 2015 Q3 | - INR | 0.0% |
| 2015 FY | - INR | -0.49% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | - INR | -2.07% |
| 2014 Q4 | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2013 FY | - INR | -15.26% |
| 2012 FY | - INR | 18.65% |
| 2011 FY | - INR | 3.54% |
| 2010 FY | - INR | 18.26% |
| 2009 FY | - INR | 46.24% |
| 2008 FY | - INR | -7.43% |
| 2007 FY | - INR | 73.68% |
| 2006 FY | - INR | 10.74% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 84.032% |
| Hester Biosciences Limited | 539.47 Million INR | -184.648% |
| Aarti Drugs Limited | 3.24 Billion INR | 52.731% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 60.721% |
| Albert David Limited | 1.04 Billion INR | -46.887% |
| Alembic Limited | 1.11 Billion INR | -37.556% |
| Alkem Laboratories Limited | 24.19 Billion INR | 93.653% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -1240.155% |
| Bajaj HealthCare Limited | 406.23 Million INR | -278.003% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -11715.866% |
| Brooks Laboratories Limited | 41.72 Million INR | -3579.999% |
| Eris Lifesciences Limited | 6.98 Billion INR | 78.02% |
| FDC Limited | 3.38 Billion INR | 54.64% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 77.625% |
| Gufic Biosciences Limited | 1.48 Billion INR | -3.722% |
| Hikal Limited | 2.69 Billion INR | 42.962% |
| Ind-Swift Limited | 1.06 Billion INR | -44.178% |
| Innova Captab Limited | 1.66 Billion INR | 7.955% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 41.088% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -374.739% |
| Jubilant Pharmova Limited | 8 Billion INR | 80.82% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -14.313% |
| Lupin Limited | 36.96 Billion INR | 95.846% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -777.751% |
| Medico Remedies Limited | 129.09 Million INR | -1089.513% |
| Morepen Laboratories Limited | 1.72 Billion INR | 11.029% |
| Orchid Pharma Limited | 1.41 Billion INR | -8.203% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 50.052% |
| RPG Life Sciences Limited | 1.28 Billion INR | -19.828% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -434.258% |
| Sigachi Industries Limited | 883.39 Million INR | -73.828% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 154.417% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 67.168% |
| Themis Medicare Limited | 562.6 Million INR | -172.942% |
| Unichem Laboratories Limited | 742.35 Million INR | -106.854% |
| Vaishali Pharma Limited | 31.71 Million INR | -4742.452% |
| Wanbury Limited | 985.49 Million INR | -55.82% |
| Windlas Biotech Limited | 781.72 Million INR | -96.437% |
| ZIM Laboratories Limited | 462.09 Million INR | -232.309% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 77.621% |
| Ipca Laboratories Limited | 13.29 Billion INR | 88.454% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.89% |
| Venus Remedies Limited | 711.8 Million INR | -115.733% |
| Sakar Healthcare Limited | 393.26 Million INR | -290.469% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.515% |
| Divi's Laboratories Limited | 25.43 Billion INR | 93.962% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 34.844% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.534% |
| Sequent Scientific Limited | 549.8 Million INR | -179.3% |
| Laurus Labs Limited | 8 Billion INR | 80.82% |
| Neuland Laboratories Limited | 4.74 Billion INR | 67.659% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 83.55% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 86.463% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.269% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -125.293% |
| Wockhardt Limited | 1.08 Billion INR | -42.184% |
| Bal Pharma Limited | 345.59 Million INR | -344.336% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.26% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -3.824% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -572.991% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 75.168% |
| Shilpa Medicare Limited | 2.58 Billion INR | 40.665% |
| Valiant Laboratories Limited | 12.73 Million INR | -11954.243% |
| Ajanta Pharma Limited | 12.56 Billion INR | 87.779% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -3299.956% |
| Granules India Limited | 8.6 Billion INR | 82.152% |
| Medicamen Biotech Limited | 245.66 Million INR | -525.088% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -256.885% |
| Piramal Enterprises Limited | -3.86 Billion INR | 139.771% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.614% |
| NATCO Pharma Limited | 18.79 Billion INR | 91.83% |
| Suven Life Sciences Limited | -992.78 Million INR | 254.676% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1956.214% |
| Strides Pharma Science Limited | 3.76 Billion INR | 59.211% |
| Indoco Remedies Limited | 2.64 Billion INR | 41.989% |
| Alpa Laboratories Limited | 229.96 Million INR | -567.761% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2459.542% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 141.152% |